

May 18, 2015

SciBase supports the physicians at the Karolinska University Hospital during the Euromelanoma Week

SciBase, that develops and markets a new method for the early detection of malignant melanoma, will today be present on-site at the Karolinska University Hospital to support the physicians in the detection of malignant melanoma.

The Karolinska University Hospital is a participant in the Euromelanoma Week, a European initiative to increase the awareness of skin cancer and especially malignant melanoma, it's most dangerous form. The Karolinska University Hospital is one of 45 organizations in Sweden that will accept patients without a referral to examine suspicious skin lesions.

Nevisense, which has been developed by SciBase, is an aid in the detection of malignant melanoma. The cancer is often hard to detect and the current diagnostic methods are based on visual detection, which is dependent upon the individual physicians experience and knowledge. Nevisense is the first non-visual method and as such an important objective complement to the current methods.

- Our clinical studies have demonstrated that Nevisense has a very high sensitivity to detect malignant melanoma but can also help to reduce the number of unnecessary biopsies. We hope that many patients will visit Karolinska during Euromelanoma week to have their lesions examined and that we, with Nevisense, can be of assistance in the difficult task to correctly identify the lesions that are melanoma, says Simon Grant, CEO of SciBase.

Skin cancer is one of the most common cancers in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to age 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority [75%] of deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly and the key to a successful treatment is early detection.

About Euromelanoma 2015

Euromelanoma 2015 is an European investment in the prevention and early detection of malignant melanoma and other forms of skin cancer. In Sweden the Euromelanoma week runs from May 18 to May 22. Dermatology clinics, spread through the country, offer together more than 5,000 examinations without referrals. All the clinics utilise appointments (no drop-ins). Ordinary patient-fees and cost ceilings apply. You can find all the participating clinics in Sweden at www.euromelanoma.com/sweden.

For further information please visit www.scibase.com or contact:

Simon Grant, VD
Tel: +46 72 887 43 99
E-mail: simon.grant@scibase.com

About SciBase and Nevisense

SciBase is a Swedish medical technology company founded in 1998 that has developed Nevisense, a point-of-care device for the accurate detection of malignant melanoma. Nevisense has emerged from more than 20 years of research at The Karolinska Institute in Stockholm and at SciBase. The device is designed to provide additional information when evaluating lesions with a suspicion of melanoma. Nevisense is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. The CE-marked system consists of an electrode on a hand-held probe connected to a small portable device performing the analysis and displaying the result.

A video describing the Nevisense method is available on: <http://scibase.se/en/the-nevisense-product> and further information is also available on www.scibase.com.